Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been established as the indisputable tool in the oncological arena to diagnose, stage/restage, and report treatment response for various tumor malignancies. FDG uptake mostly identifies pathological uptake in oncological scans with the tracer on PET studies; however, benign uptakes are also commonly seen. Reported here is a benign case of increased uptake of the FDG on a PET with computed tomography scan in the gallbladder (GB) of a patient being screened for a known carcinoma breast. The benign accumulation of the tracer is seen in the GB to various degrees and this phenomenon may occur as a result of FDG excretion into the bile. When interpreting clinical PET images, recognition of this phenomenon is important to avoid misdiagnosing physiological GB FDG uptake as pathological so as to avoid misinterpretations of the findings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745864 | PMC |
http://dx.doi.org/10.4103/wjnm.WJNM_82_19 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!